

Holly B Krasa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10907961/publications.pdf>

Version: 2024-02-01

12
papers

2,253
citations

840776

11
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

2255
citing authors

#	ARTICLE	IF	CITATIONS
1	Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease. <i>New England Journal of Medicine</i> , 2012, 367, 2407-2418.	27.0	1,267
2	Endotoxin Inhibits the Reproductive Neuroendocrine Axis While Stimulating Adrenal Steroids: A Simultaneous View from Hypophyseal Portal and Peripheral Blood. <i>Endocrinology</i> , 1997, 138, 4273-4281.	2.8	136
3	Endocrine Alterations That Underlie Endotoxin-Induced Disruption of the Follicular Phase in Ewes. <i>Biology of Reproduction</i> , 2000, 62, 45-53.	2.7	135
4	Tolvaptan in Autosomal Dominant Polycystic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 2499-2507.	4.5	133
5	Clinical Course of Patients With Hyponatremia and Decompensated Systolic Heart Failure and the Effect of Vasopressin Receptor Antagonism With Tolvaptan. <i>Journal of Cardiac Failure</i> , 2013, 19, 390-397.	1.7	130
6	Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2011, 80, 295-301.	5.2	115
7	Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal) Trial. <i>Journal of the American Society of Nephrology</i> , 2011, 57, 692-699.	1.9	115
8	Short-term renal hemodynamic effects of tolvaptan in subjects with autosomal dominant polycystic kidney disease at various stages of chronic kidney disease. <i>Kidney International</i> , 2013, 84, 1278-1286.	5.2	72
9	Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. <i>American Journal of Kidney Diseases</i> , 2015, 65, 833-841.	1.9	68
10	Albuminuria and tolvaptan in autosomal-dominant polycystic kidney disease: results of the TEMPO 3:4 Trial. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1887-1894.	0.7	46
11	Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure. <i>American Journal of Health-System Pharmacy</i> , 2011, 68, 328-333.	1.0	30
12	Pooled Data Analysis of the Long-Term Treatment Effects of Tolvaptan in ADPKD. <i>Kidney International Reports</i> , 2022, 7, 1037-1048.	0.8	6